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Abstract The development of new therapeutic options for
renal tumors has lead to the need of a pretherapeutic diag-
nosis for an increasing proportion of patients presenting
with a renal mass. This need is particularly important for a
small, incidentally discovered renal mass (less than 4 cm) as
it can be a benign lesion in a significant percentage of cases.
Recent studies have shown that needle biopsy is an accurate
and safe method allowing for a precise histopathological
diagnosis of the mass in most cases. The aims of the biopsy
are (1) to assess the benign or malignant nature of the lesion,
(2) to assess the primary or secondary nature of the lesion,
and (3), in case of a primary malignancy, to determine
histological prognostic factors, such as the tumor type. This
review, based on the most recent literature and our own
experience, is intended to provide a practical approach to
the diagnosis, relying on appropriate morphologic assess-
ment and the use of immunohistochemistry.
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Introduction
In the past, complete surgical resection (radical nephrectomy)
without preoperative histological assessment has long been
considered the gold standard for the management of renal
masses, as indeed the majority of solid renal tumors are
malignant primaries for which surgical management allows
optimal staging and treatment. In that context, core needle
biopsies were mostly restricted to situations where the indica-
tion of surgery was questionable, i.e., in cases of high suspi-
cion of a benign tumor, metastasis, lymphoma, or abscess [1].
Other factors reported to compound preoperative biopsies
included an overestimated risk of noncontributive samples,
tumor dissemination along the needle track, and hemorrhagic
complications [2].
For the past few years, the number of biopsies for renal
masses has virtually exploded. The increased use of cross-
sectional imaging for other pathologies has lead to the
discovery of renal masses, especially of small size, without
radiological criteria allowing to determine the nature of the
tumor. Nowadays, more than half of all renal tumors are
incidentally detected [3]. Moreover, a significant minority
(between 15 and 35 %) of these small renal masses, by
definition less than 4 cm, consist of benign lesions which
do not require surgical removal [4–7]. At the same time,
new therapeutic options including partial nephrectomy,
imaging-guided ablative therapy (using radiofrequency ab-
lation, high intensity focused ultrasound, or cryotherapy),
active surveillance, or systemic neoadjuvant therapy have
emerged for the treatment of renal cell carcinoma [8, 9]. In
these cases (with the exception of partial nephrectomy),
these new therapeutic options require pretherapeutic patho-
logical diagnosis. Moreover, the diagnostic accuracy of the
biopsy has increased in the last decade [10], as a result of
both the improvement in biopsy techniques and the devel-
opment of immunohistochemistry panels allowing the iden-
tification of almost all tumor subtypes and the newly
described entities.
There are currently numerous conditions for which the
indication of a biopsy can be discussed: (1) the discovery of
a small renal mass because it can correspond to a benign
lesion for which a partial or radical nephrectomy would not
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be required; (2) in metastatic patients eligible for a systemic
therapy with no previous pathology documentation, in order
to select therapy by classifying the tumor; (3) a previous
history of extrarenal malignancy raising the differential di-
agnosis of a metastasis or when suspecting lymphoma; (4) a
mass associated with a febrile urinary tract infection, in this
situation the differential diagnosis includes renal abscess or
an inflammatory pseudotumor such as xanthogranulomatous
pyelonephritis
Therefore, the aim of a pretherapeutic biopsy is to
determine (1) the benign or malignant nature of the lesion,
(2) the primary or secondary nature of a malignant lesion,
and (3) the tumor type. Lesions that are mostly cystic are
currently not an indication for pretherapeutic biopsy be-
cause of the difficulty to obtain representative samples of
the lesion. The prognosis of cystic lesions can be deter-
mined to some extent by appropriate imaging modalities
(mainly ultrasound, CT scan, and MRI) using Bosniak’s
classification [11].
This review is intended to provide a practical approach to
the diagnosis of renal core biopsies performed for investi-
gating kidney masses. It is based on the most recent litera-
ture concerning the subject and on our own experience.
Technical considerations and diagnostic accuracy
Biopsies are generally performed by the radiologist under
US or helical CT guidance, with the patient in prone posi-
tion under local anesthesia. CT is performed immediately
after needle removal to exclude postbiopsy complications.
The recommendation is to use 18-gauge (G) needles (yield-
ing 1.7×0.1-cm cores) and to obtain at least two cores in the
periphery of the tumor and in nonnecrotic areas [12]. In a
prospective ex vivo study conducted on nephrectomy speci-
mens, aimed to compare the yield of 14-, 18-, and 20-G core
needle biopsies, Breda et al. [13] found that three biopsies
with 14- and 18-G needles allowed to obtain an adequate
diagnosis of solid renal masses in 94 and 97 % of the cases,
respectively, while the yield of 20-G needles was signif-
icantly inferior (81 %). Although fine needle aspiration is
not the topic of this review, it is worth mentioning that in
some centers, smear preparations are examined extempo-
raneously to verify the adequacy of the sample. Others
use it as a diagnostic tool, with an accuracy close to that
of needle biopsies, especially in conjunction with immu-
nocytology [16].
The samples are fixed in formalin and submitted as one
core per cassette for standard processing and paraffin em-
bedding. In our institution, sections from three levels are
stained with hematoxylin and eosin for histopathological
evaluation, and four additional sections per level are kept
unstained for special stains and/or immunohistochemistry.
When an adequate sample is obtained, the ability to
distinguish benign from malignant lesions is excellent and
almost reaches 100 % of the cases. Indeed, in an in vivo
study, all oncocytomas were well identified [14]. The ability
to determine the histological subtype of renal cell carcinoma
(RCC) is excellent, especially when adding adequate
immunostain with an accuracy of 90 % overall and
99 % among the four most common subtypes [15].
Interpretation
Renal cell tumors are currently classified according to the
World Health Organization (WHO) system which defines
tumor entities based on their pathological features, clinical
behavior, and genetic alterations (Table 1) [17]. The
histopathological diagnosis primarily relies on the exam-
ination of routinely stained sections, by taking into
account (1) the cytologic features of the tumor cells
(i.e., clear, eosinophilic, chromophobic, oncocytic, spindle
cells), and (2) the tumor architecture (i.e., solid, acinar, papil-
lary). Assessment of the growth pattern and associated stroma
may be of interest for the identification of some renal cell
tumor entities and also in the differential diagnosis with non-
renal cell tumors.
Clear cell tumors
Clear cell renal cell carcinoma
Clear cell renal cell carcinoma (CCRCC), by far the com-
monest malignant renal epithelial neoplasm, represents ap-
proximately 60 % of renal cortical tumors. Importantly,
however, all clear cell lesions are not clear cell renal cell
carcinomas, and clear cell renal cell carcinoma is not in fact
always composed of clear cells, a reason why some authors
advocate the designation “conventional” renal cell carcino-
ma. Nevertheless, the recommended nomenclature accord-
ing to the WHO classification remains “clear cell” renal cell
carcinoma [17].
In typical cases, the biopsy shows a proliferation of clear
cells, possibly admixed with an eosinophilic granular cell
component, with a solid or acinar architecture. A prominent
delicate and branching vascularization network is character-
istic and almost always observed. Secondary changes such
as focal fibrosis or hyalinization, geographic necrosis, and
focal hemorrhage are frequent. When typical features are
observed, the diagnosis is straightforward by morphology
and additional ancillary techniques are usually not necessary
(Fig. 1). When facing unusual morphology (predominantly
granular eosinophilic component or predominantly papillary
architecture), immunohistochemistry is helpful to confirm
the diagnosis.
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CCRCC expresses pan-cytokeratins (for example those
recognized by the AE1/AE3 cocktail), epithelial membrane
antigen (EMA), vimentin, and CD10 in a membranous distri-
bution. Alpha-methyl CoA racemase (AMACR) expression is
detected in up to 68 % but usually more focally than in
papillary carcinoma. Cytokeratin 7 (CK7) expression is weak
and focal. Less than 10% of the cases show focal positivity for
CD117 while the majority of cases are negative. HMB-45 is
negative. Antibodies raised against carbonic anhydrase IX
(CA-IX), a membranous enzyme acting to regulate both in-
tracellular and extracellular pH and whose expression is in-
duced by hypoxie, have been recently characterized and found
of interest for diagnostic purposes. The majority (>85 %) of
CCRCC strongly express CA-IX [18, 19]. Importantly, only a
membranous pattern is characteristic for clear cell RCC, while
cytoplasmic staining is not specific and often observed focally
with preferential distribution around necrotic areas in other
nonclear cell renal cell neoplasms.
Nuclear grading as per the Fuhrman grading system
should be assigned because it is one of the most important
prognostic factors in organ-confined carcinoma [20] and
because some authors advocate that in elderly and unfit
patients, low-grade carcinoma can be initially observed or
ablated rather than operated on, while the former treatments
are not appropriate for high-grade RCC [7]. However, the
concordance is low (less than 50 %) between the grades
assessed on paired biopsies and surgical specimens, reflect-
ing intratumor heterogeneity [21]. Alternatively, several
authors have advocated to combine lower grades (1 and 2)
and higher grades (3 and 4) into a two-tier grading system,
which has been shown to reduce the discrepancies between
pre- and postsurgical grade assessments [21].
Table 1 Classification of renal cell tumors (adapted from the WHO
histological classification of tumors of the kidney, 2004)
Renal cell tumors
Clear cell renal cell carcinoma
Multilocular clear cell renal cell carcinoma
Papillary renal cell carcinoma
Type I
Type II
Chromophobe renal cell carcinoma
Carcinoma of the collecting ducts of Bellini
Renal medullary carcinoma
Xp11 translocation carcinomas
Carcinoma associated with neuroblastoma
Mucinous tubular and spindle cell carcinoma
Renal cell carcinoma, unclassified
Papillary adenomaa
Oncocytomaa
Tumors recently described, not yet listed in
the WHO classification
Clear cell papillary renal cell carcinoma
Clear cell carcinoma with leiomyomatous stroma
Oncocytic type papillary carcinoma
Metanephric tumors
Nephroblastic tumors
Mesenchymal tumors
Mixed mesenchymal and epithelial tumors
Neuroendocrine tumors
Hematopoietic and lymphoid tumors
Germ cell tumors
Metastatic tumors
a Benign lesions
a b
Fig. 1 Core biopsy of a clear
cell RCC. Low magnification
shows a solid epithelial
proliferation (a, hematoxylin
and eosin, ×2). Higher
magnification shows a
proliferation of large polygonal
cells with clear or finely
granular cytoplasm, with round
hyperchromatic nuclei
(b, hematoxylin and eosin,
original magnification ×12). In
such a case, no ancillary
techniques are necessary to
confirm the diagnosis
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Differential diagnosis
Clear cell RCC can be confused with a variety of other
benign or malignant lesions composed of clear cells (Table 2)
[22]. In case of diagnostic problems, immunohistochemistry is
a helpful adjunct to careful morphologic evaluation to distin-
guish between the several diagnostic possibilities (Table 3).
Chromophobe renal cell carcinoma Chromophobe carcino-
ma is generally composed of an admixture of clear and
eosinophilic cells. The cellular contours are sharply delin-
eated with thick membranes accounting for a pseudovegetal
aspect. In the clear cells, the nuclei are characteristically
wrinkled. Vascularization is less prominent than in CCRCC.
The immunohistochemical profile differs from that of
CCRCC since chromophobe carcinoma usually does not
diffusely express vimentin, CD10, or CA-IX, while con-
versely CK7 and CD117 are both diffusely expressed.
Clear cell papillary renal cell carcinoma Clear cell papil-
lary renal cell carcinoma, first described in the setting of
end-stage kidney diseases, may also occur in the absence of
impaired renal function. The few cases with documented
clinical follow-up suggest an indolent course. These tumors
are usually well circumscribed, encapsulated, and unilateral
and measure less than 5 cm. In typical cases, there is a
delicate papillary architecture with thin fibrovascular
septa lined by a single layer of clear cell. The nuclei,
generally relatively bland, are arranged in a linear fashion,
centrally, or in the upper pole of the cytoplasm. Purely solid
forms do exist as well, with a cord-like or trabeculated pattern,
reminiscent of that of sex-cord neoplasms. The immunohisto-
chemical profile is quite characteristic, and the distinguishing
features from CCRCC are a strong and diffuse CK7 expres-
sion and usual negativity for CD10 [23, 24].
Leiomyomatous renal cell carcinoma Recently, a few cases
of renal cell carcinoma with angioleiomyoma-like stroma
have been described [24, 25]. These tumors which appear to
run an indolent clinical course are composed of nests, cords,
and sheets of epithelial clear cells, with low nuclear
grade. This epithelial proliferation is dissociated by a
stroma featuring mature smooth muscle appearance.
The differential diagnosis includes not only CCRCC
with fibrohyalinized stroma but also angiomyolipoma
and sarcomatoid CCRCC with sarcomatoid component.
Unlike CCRCC, the epithelial component of leiomyom-
atous RCC expresses CK7 and high molecular weight
CK, and the stroma shows smooth muscle cell differ-
entiation evidenced by positivity for smooth muscle
actin and desmin. Leiomyomatous RCC is negative for
melanocytic markers, at variance with angiomyolipoma, and
the absence of significant atypia in the stromal component
distinguishes it from sarcomatoid carcinoma (Fig. 2).
Translocation-associated renal carcinomas The presence
of a mixed alveolar/papillary architecture, an admixture
of large clear and eosinophilic cells, and calcifications,
especially in a young patient, are features suggestive for
a translocation carcinoma. Translocation carcinomas are
commonly negative for all epithelial markers, although
focal positivity may be observed, especially for EMA.
CA-IX, CD10, and vimentin can be expressed, like
AMACR, Melan-A, and human melanoma black-45
(HMB45). As discussed below, the diagnosis can be
immunohistochemically proven by the nuclear positivity
of transcription factor E3 (TFE3) or transcription factor
EB (TFEB) or by fluorescence in situ hybridization
(FISH) assays [26].
Angiomyolipoma with epithelioid component Angiomyoli-
pomas are composed of variable combinations of spin-
dle or epithelioid smooth muscle cells sometimes with
clear cytoplasm, adipose tissue, and abnormal thick-
walled blood vessels. In the presence of abnormal ves-
sels or fat, the diagnosis is usually straightforward but
in the presence of a fat-poor lesion with prominent epithe-
lioid clear cell component; it can be confused with clear cell
RCC. Immunohistochemistry is useful in this setting since the
epithelioid cells of angiomyolipoma do not express any epi-
thelial markers, CA-IX, CD10, or AMACR, while smooth
muscle actin, desmin, HMB45, and Melan-A will be at least
focally positive.
Histiocytic infiltrates Inflammatory lesions or pseudotumors
with a high macrophage content can be present on biopsies as
clear cell-rich lesions, which may be mistaken as CCRCC.
Careful evaluation of the cytologic features will show xan-
thomatous rather than granular cytoplasm and consistently
low-grade nuclear features. Another hint is the frequent ad-
mixture of other inflammatory cells and the presence of pre-
served normal or atrophic renal structures, while conversely
carcinoma infiltrates in a pushing and destructive manner. In
Table 2 Differential diagnosis of clear cell renal cell carcinoma
Malignant neoplasms
Chromophobe renal cell carcinoma
Clear cell papillary renal cell carcinoma
Clear cell carcinoma with leiomyomatous component
Translocation renal cell carcinoma
Benign lesions
Angiomyolipoma
Histiocytic infiltrates
Adrenocortical tissue
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cases of doubt, a limited immunohistochemistry panel with
antibodies directed against CD68 and cytokeratins can solve
the differential diagnosis (Fig. 3).
Adrenocortical tissue Adrenocortical tissue—either normal
or neoplastic and benign or malignant—may be misinterpreted
as CCRCC. Biopsy sampling of adrenocortical tissue is more
likely to occur when dealing with an upper pole lesion, but one
has to be aware of the possibility of renal–adrenal fusion or
ectopic adrenal tissue as well. Compared to CCRCC, adreno-
cortical cells have a more granular cytoplasm and are arranged
in a trabecular or nested rather than acinar pattern. Upon
immunostaining, adrenocortical tissue lacks expression of
EMA or CA-IX and conversely is positive for inhibin, calreti-
nin, synaptophysin, and Melan-A. In a minority of cases,
CKAE1-AE3 and CD10 may be positive [22, 27].
a
b c
Fig. 2 Core biopsy of a
leiomyomatous RCC showing a
tubuloacinar clear cell epithelial
component admixed with a
leiomyomatous component
(a, hematoxylin and eosin,
original magnification ×20).
Intense and diffuse expression of
CK7 in the epithelial component
(b, immunoperoxidase, ×10).
Intense expression of actin in the
leiomyomatous component
(c, immunoperoxidase, ×10)
Table 3 Immunohistochemistry for the differential diagnosis of RCC with clear cell features
VIM PanCK CK7 CA-IX CD10 AMACR CD117
Clear cell RCC ++ + −/+ ++ ++ +/− or − −
Chromophobe RCC − ++ ++ or − − − − ++
Translocation RCC ++ − − − −/+ +/− or − −
Leiomyomatous RCC ++ ++ ++ ND ND ND ND
Clear cell papillary RCC ++ ++ ++ ND − ND −
ND not determined, RCC renal cell carcinoma, VIM vimentin, ++ strong positivity in >75 % of tumor cells, +moderate positivity in >75 % of tumor
cells, +/− positivity in 50–75 % of tumor cells, −/+ positivity in <50 % of tumor cells, − absence of significant expression
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Eosinophilic cell tumors
Chromophobe cell carcinoma and oncocytoma
Chromophobe renal cell carcinoma and oncocytoma ac-
count for the majority of eosinophilic renal cell tumors.
The distinction is clinically of paramount importance, given
distinct managerial consequences. The differential diagnosis
which may be difficult due to overlap in morphological
features is greatly aided by the use of ancillary techniques.
Chromophobe RCC (Fig. 4a–d) is composed of clear,
eosinophilic, or an admixture of clear and eosinophilic ter-
ritories. Compared to the classical clear cell variant, in the
eosinophilic variant, the cells are generally smaller, with
regular and small nuclei, sometimes binucleated, often with
a perinuclear halo. The stroma can be focally abundant and
fibroedematous. Oncocytomas (Fig. 4e–h) are composed of
cells with abundant eosinophilic cytoplasm without sharp
delineation of the cell borders. The nuclei are round or with
smooth contours and may show atypias, in the form of large
irregular hyperchromatic bizarre nuclei. Another character-
istic feature of the oncocytoma is the presence of a focally
abundant fibroedematous stroma, but this finding is not
specific [28].
The expression of CK7 (Fig. 4c, g) is the most discrim-
inant available marker for the differential diagnosis (Table 4),
usually intense and diffuse in chromophobe renal cell carci-
noma while negative or very focal—in single cells or small
clusters of cells—in 95 % of oncocytomas. However, up to
20 % of chromophobe carcinomas lack CK7 expression;
hence, negativity of CK7 does not exclude this diagnosis.
CD117 (Fig. 4d, h) is another useful marker showing a diffuse
cytoplasmic expression with peripheral accentuation in chro-
mophobe renal cell carcinoma while being more often only
focally expressed in oncocytoma (essentially in the cytoplasm
without membrane reinforcement) [29, 30]. CD10 and
AMACR are usually negative in both entities, and expression
of vimentin is variable, negative in chromophobe RCC, and
possibly focally positive in a large proportion of oncocytomas
[31]. CA-IX can be positive in perinecrotic areas of a chro-
mophobe RCC and is consistently negative in oncocytoma.
Hale’s colloidal iron staining, traditionally recommended as a
marker for chromophobe carcinoma, is now obsolete because
of technical and interpretation issues.
Clinicians may be doubtful when a diagnosis of oncocy-
toma is rendered on a biopsy because of the possibility of a
hybrid oncocytic/chromophobe tumor of which the poten-
tially malignant component would not have been sampled.
However, except in Birt–Hogg–Dubé syndrome or in the
setting of renal oncocytomatosis, hybrid tumors appear ex-
ceedingly rare, less than 2 % of oncocytoma and chromo-
phobe RCC and do not justify a surgical management for all
oncocytoma diagnosed on needles. Moreover, the behavior
of these mixed neoplasms seems to be indolent [32].
Differential diagnosis
Other renal cell neoplasms less commonly presenting as
eosinophilic cell lesions include a subset of CCRCC (dis-
cussed above) and papillary renal cell carcinomas (type II
and oncocytic) which may comprise solid areas mimicking
oncocytoma [33, 34]. In our institution, when dealing with
a c
b
Fig. 3 Xanthogranulomatous
pyelonephritis with
pseudoglandular architecture of
the foamy histiocytic infiltrate
(a, hematoxylin and eosin,
original magnification ×20).
Negativity of the pan-keratine
AE1/AE3 (b, immunoperoxi-
dase, ×20) and expression of
CD68 (c, immunoperoxidase,
×20)
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small specimen, eosinophilic cell tumors are systematically
immunostained for vimentin, CD10, AMACR, CD117, and
CK7 (Table 4). In addition, PS100 may be added to the
panel as the possibility of metastatic melanoma should also
always be borne in mind. If angiomyolipoma is suspected,
expression of actin, desmin, HMB45, and Melan-A is also
assessed. Exceptional examples of sarcomatoid carcinoma
may exhibit rhabdoid features and present as an eosinophilic
cell tumor (Fig. 5).
Papillary tumors
A variety of primary renal neoplasms or metastases may
show a focal or extensive papillary pattern (Table 5). Once
a b
c d
e f
g h
Fig. 4 Chromophobe RCC, mixed clear cell, and eosinophilic type (a–
d). The tumor is composed of large cells with abundant cytoplasm,
sharp delineation of the cell borders, and wrinkled nuclei or perinuclear
halo. (a, b, hematoxylin and eosin, original magnification ×2 and ×10).
Diffuse expression of CK7 (c, immunoperoxidase ×20) and diffuse and
intense membranous and cytoplasmic expression of CD117 (d,
immunoperoxidase ×20). Oncocytoma (e–h). Core biopsy comprising
nests of eosinophilic cells with regular nuclei disposed in an abundant
fibroedematous stroma (e, f, hematoxylin and eosin, original magnifi-
cations ×2 and ×20). Positivity of isolated or small cluster of cells for
CK7 (g, immunoperoxidase ×20). Cytoplasmic expression of CD117
without membranous enhancement (h, immunoperoxidase ×20)
Table 4 Immunohistochemistry
for the differential diagnosis
renal tumors with
eosinophilic cells
Vim CK7 CA-IX CD10 AMACR CD117
Chromophobe RCC − ++ or − − −/+ − ++
Oncocytoma −/+ or − − or −/+ − −/+ − +/−
Clear cell RCC ++ −/+ ++ ++ +/− or − −
Papillary type II RCC ++ + or +/− − + ++ −
Papillary oncocytic RCC ++ + or +/− − ND ++ −
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papillary pattern is recognized, morphological analysis should
assess the cytoplasmic features (eosinophilic, basophilic, or
clear cell), the nuclear grade, the number of layer of cells
lining the papilla, and the presence of foamy histiocytes
(Fig. 6). In case of a carcinoma featuring a papillary architec-
ture, immunohistochemistry may suggest the renal cell deri-
vation by the positivity of AMACR and CK7. Vimentin and
CD10 are generally at least focally positive. If these markers
are lacking, metastatic, urothelial, or collecting duct carcino-
ma should be considered (discussed later). Even in the ab-
sence of a clear papillary architecture, the presence of foamy
histiocytes is suggestive for papillary RCC. This diagnosis
should also be entertained when dealing with an eosinophilic
cell lesion, even of solid architecture (see above). Metanephric
adenoma, a rare benign entity, must also be considered in the
differential diagnosis of papillary neoplasms.
Papillary renal cell carcinoma
Papillary RCC comprises type I, type II, and the oncocytic
variant. It is of interest to determine the subgroup of the
papillary carcinoma because their prognoses are different.
The type I and oncocytic variants are considered low-grade
malignant neoplasm while type II is overall more aggressive
with a prognosis similar to or worse than that of a clear cell
RCC.
Papillary carcinoma, type I This entity features a typical
and homogeneous morphology characterized by a delicate
papillary architecture lined by a single layer of basophilic
cells, with low nuclear grade (Fuhrman 1 or 2). Accumula-
tion of foamy histiocytes in the vascular cores is virtually
constant. Necrosis and cholesterol clefts may be abundant.
AMACR, CK7, vimentin, and CD10 are almost always
expressed (Table 4). Some tumors show a prominent tubular
architecture with only minimal papillary pattern, which may
be the only component sampled on biopsy. The presence of
foamy macrophages is helpful to distinguish this tumor type
from the others of tubular architecture (Fig. 7).
Papillary carcinoma, type II Papillary carcinoma type II is
a heterogeneous group of tumors with respect to their mor-
phology, immunophenotype, molecular features, and prog-
nosis. Expression of CK7 is not as systematic as in type I but
AMACR is usually expressed. In general, the papillae are
lined by one or several layers of eosinophilic cells. Fuhrman
nuclear grade is higher than in type I (generally 3 or 4), and
macrophages are less numerous. Necrosis and cholesterol
deposits are frequent.
Oncocytic papillary renal cell carcinoma Oncocytic papil-
lary renal cell carcinoma, formerly included in the group of
type II carcinomas, was recently individualized because of
its more indolent behavior. It consists of a proliferation of
oncocytic cell with round nuclei and large nucleoli. At
variance with papillary carcinoma type II, the papillae are
mostly lined by a single layer of tumor cells. Foamy macro-
phages are more frequent than in papillary type II RCC. In all,
the oncocytic type of papillary RCC is best described as a
tumor resembling papillary type I with oncocytic cells [33].
Microphthalmia-associated transcription factor family–
TFE3 translocation-associated renal carcinomas Translo-
cation renal cell carcinoma comprises a group of neoplasms
characterized by translocation involving genes encoding
transcription factors of the microphthalmia-associated tran-
scription factor family, TFE3, or less frequently TFEB, with
various gene partners. The most frequent translocations
Fig. 5 Rhabdoid RCC. Sarcomatoid component presenting as rhab-
doid tumor (hematoxylin and eosin ×20). Expression of CK and INI1
(not shown)
Table 5 Renal tumors with possibly focal or extensive
papillary architecture
Renal tumors of papillary architecture
Papillary RCC type I and II, papillary oncocytic RCC
Translocation RCC
Clear cell papillary RCC
Hereditary leiomyomatosis and renal cell cancer
syndrome related RCC
Other renal tumors possibly comprising a papillary
component
Clear cell RCC
Collecting duct carcinoma
Metanephric adenoma
Mucinous tubular and spindle cell carcinoma
Urothelial carcinoma
Chromophobe RCC
Oncocytoma
Metastasis
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involve TFE3 with alveolar soft part sarcoma locus or
papillary renal cell carcinoma. First described in pediatric
population, translocation RCC also occurs in adults ac-
counting for 1 to 4 % of RCCs. Translocation RCC is often
cytoplasmic 
features
Clear cells
Features of clear 
cell RCC present ?
yes
Clear cell RCC
Check for typical 
immunohistochemical 
profile  (Cf table 3)
No
Fuhrman
nuclear grade
High grade
Translocation RCC
Admixed with 
eosinophilic 
component
alveolar architecture
microcalcification
Low grade 
with polarized 
nuclei
Clear cell 
papillary RCC
Diffuse and 
intense 
expression of 
CK7                     
Eosinophilic cells
Papilla's 
stratification
Unistratification
Oncocytic 
papillary RCC
Pluristratification
Papillary type 
II RCC
Translocation RCC
Admixed with clear cell 
component
alveolar architecture
microcalcification
Basophilic cells
small monotonous 
nuclei
glomeruloid 
structures 
hyalinized stroma 
no
Papillary type 
1 RCC
yes
metanephric 
adenoma 
check for positivity of 
WT1
Fig. 6 Algorithm for assessment of papillary tumors on core renal biopsies (metastases are not listed but also enter in the differential diagnosis)
a b
c d
Fig. 7 Papillary RCC probably
of type I with prominent tubular
architecture (a, hematoxylin
and eosin ×4). The presence of
foamy histiocytes is a useful hint
to the diagnosis (b, hematoxylin
and eosin ×20). The typical
immunohistochemical profile
includes diffuse and strong
expression of AMACR
(c, immunoperoxidase ×20) and
expression of CK7, which
was focal in this case
(d, immunoperoxidase ×20)
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present with advanced disease and distant metastasis and
carries a dismal prognosis.
Characteristic features of translocation carcinomas in-
clude the presence of a mixed alveolar/papillary architecture
with an admixture of large clear and eosinophilic cells, the
presence of calcifications, and high nuclear grade. Upon
immunohistochemistry, translocation carcinomas are usually
negative for keratin expression, and hence the diagnosis
should always be entertained in front of a keratin-negative
renal tumor. EMA can be focally positive, and there is a
variable expression of vimentin, AMACR, Melan-A, and
HMB45. The diagnosis is definitely proven by the demon-
stration of TFE3 or TFEB expression [26] and/or by evidenc-
ing the gene rearrangement by FISH assay [35].
Metanephric adenoma Metanephric adenoma is a rare be-
nign neoplasm composed of small primitive cells resembling
early metanephric tubular differentiation. Histologic features
encompass small acini, papillary, and glomeruloid structures
composed of monotonous cells with small nuclei and minimal
blue cytoplasm. The stroma is often hyalinized and may be
abundant. Mitoses are rare or absent. The papillary component
may resemble type 1 papillary RCC but the nuclei are smaller,
the cytoplasm is less abundant, and CK7 is usually less
diffusely positive than in papillary carcinoma type 1. AMACR
is positive in both entities. WT1 is helpful, showing often
diffuse nuclear positivity in metanephric adenoma [36].
Tumors comprising a spindle cell component
High-grade spindle cell component
When facing a cytologically high-grade spindle cell compo-
nent, the first diagnosis to consider is a sarcomatoid carcinoma.
The probability of finding a sarcomatoid component in small
renal masses is low and increases with the tumor size. The
identification of sarcomatoid carcinoma is often supported by
the presence of an admixed cytologically high-grade epithelial
component. In case of proliferations composed exclusively of
spindle cells, immunohistochemistry for demonstration of ker-
atin and/or EMA expression is usually useful.
A large variety of primary or secondary sarcomas may
involve the kidney. One of the most frequently encountered
is synovial sarcoma. Kidney synovial sarcoma is a highly
cellular tumor in which tumor cells form short, intersecting
fascicles dissecting the native renal parenchyma. This spindle
cell solid component is often admixed with cysts of different
size lined by hobnail cells. EMA and cytokeratins can be
focally positive in the spindle cells and in the cells lining the
cyst. The diagnosis is definitely established by the demonstra-
tion of SYT-SSX fusion at the genetic level or demonstration of
the fusion transcript by molecular studies [37].
Low-grade spindle cell lesions
Angiomyolipoma is the most common primary renal tumor
with a low-grade spindle cell component. Expression of
HMB45 and Melan-A in addition to smooth muscle actin
and desmin is characteristic. Other entities in the differential
diagnosis include clear cell carcinoma with leiomyomatous
stroma (discussed above) and mucinous tubular and spindle
cell carcinoma. The latter consists of low-grade epithelial
cells in the form of elongated tubules and spindle cells,
separated by variable amounts of mucinous stroma. CK7
and AMACR are usually positive. CD10 is negative [38].
Tumors with an infiltrative pattern and desmoplasia
Desmoplasia is not a feature of most renal cell carcinomas,
which tend to grow in a pushing manner. An infiltrative
pattern of growth between residual glomeruli or tubules
brings up the differential diagnoses of collecting duct carci-
noma, the very rare renal medullary carcinoma, urothelial
carcinoma, and metastasis. In this setting, PAX2 and PAX8
transcription factors represent two potentially useful
markers for the demonstration of renal cell derivation.
Collecting duct carcinoma and renal medullary carcinoma
Collecting duct carcinoma is extremely rare (less than 1 %
of renal malignancies). It comprises a tubular or tubulopa-
pillary infiltrative growth with a desmoplastic and often
inflammatory stroma. Solid, cord-like features may be en-
countered. In case of prominent papillary architecture, pap-
illary renal cell carcinoma may be suspected but the latter
usually lacks desmoplasia.
Renal medullary carcinoma is a very rare entity occurring
almost exclusively in young patients with sickled cell trait,
viewed by some authors as an aggressive form of collecting
duct carcinoma. Intratumoral inflammatory infiltrates, most-
ly neutrophils, are a constant finding and sickle red blood
cell may be recognized. Recent data suggest consistent loss
of INI-1 expression in these tumors [39].
Urothelial carcinoma
Invasive urothelial carcinoma in the kidney usually mani-
fests as high-grade carcinoma, poorly differentiated, or with
glandular differentiation. Immunohistochemistry is helpful
to demonstrate the expression of CK7, CK20, CK5/6, and
p63. The latter is very useful for distinguishing from collect-
ing duct carcinoma [40]. Conversely, urothelial carcinoma
lacks CD10 and other renal cell markers [30] (Fig. 8).
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Metastatic carcinoma
The possibility of metastasis should be considered whenever
a renal neoplasm appears unclassifiable as a primary lesion,
i.e., any lesion not showing the classical morphologic fea-
tures of a renal carcinoma (glandular architecture,
desmoplasia, absence of clear cell, etc.) and immunohisto-
chemical expression of classic renal markers (Table 6). It is
of importance to stress that AMACR has no specificity for
renal primaries and it is expressed in many adenocarcinomas
of other origins, for example prostatic, gastric, or colorectal
[41, 42]. Themost common primary sites are lung, breast, skin
a
b
c
Fig. 8 Invasive high-grade
urothelial carcinoma (a, hema-
toxylin and eosin ×2). This field
illustrates nests of atypical cells,
desmoplastic fibrous stroma,
and residual atrophic renal
tubules (b, hematoxylin and
eosin ×10). Immunohistochem-
ical profile includes nuclear
expression of P63
(c, immunoperoxidase ×10)
Table 6 Commonly used markers for diagnostic immunohistochemistry: expression in normal kidney and in primary renal and extrarenal tumors
Normal kidney Primary renal tumors Extrarenal tumors
Vimentin Vessels Clear cell RCC Carcinoma of endometrium, thyroid,
and adrenal cortexPapillary RCC
Pan-CK Tubules and glomeruli All types of RCC except
translocation carcinoma
Carcinoma
CK7 Tubules and glomeruli Papillary RCC Variety of (adeno)carcinoma (breast, lung…)
Chromophobe RCC
Leiomyomatous RCC
Clear Cell papillary RCC may
be focal in clear cell RCC
AMACR Epithelial cells of the
renal tubules
Papillary RCC Prostate, lung, colon, stomach, ovary, breast,
endometrium, gallbladder, neuroendocrine carcinomasClear cell and translocation RCC
CA IX Not expressed Clear cell RCC Endometrium, stomach, cervix, breast, lung, liver, brain
tumors, neuroendocrine carcinomas, mesotheliomaCollecting duct carcinoma
CD10 Podocytes, proximal tubular
cell brush borders
Typical in clear cell, papillary, and
translocation RCC; can be expressed
in other renal epithelial neoplasm
Various neoplasms of epithelial, stromal, or
hematopoietic derivation
CD117 ND Chromophobe RCC Gastrointestinal stromal tumor, seminoma
Oncocytoma
PAX2 and
PAX8
Podocytes All types of primary RCC, decreased
in high grade, negative in
sarcomatoid carcinoma
Lymphoma, nephrogenic adenoma, thyroid follicular
cell neoplasmDistal tubular cells
Lymphoid cells
RCC Proximal tubular
cell brush borders
Clear cell RCC Adrenocortical tumors, breast and colon
carcinoma, embryonal carcinoma, parathyroid tumors,Papillary RCC
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(malignant melanoma), contralateral kidney, gastrointestinal
tract, ovary, and testis [43]. Renal metastases appear common-
ly in the late stages of evolution whereas renal metastasis as
the initial manifestation of the primary is highly unusual.
Angiomyolipoma
Angiomyolipoma is a benign neoplasm that belongs to the
perivascular epithelioid cell (PEC)-oma family of tumors.
Its classical triphasic pattern associating variable amounts of
adipose tissue, spindle or epithelioid smooth muscle cells,
and abnormal thick-walled blood vessels is usually easily
recognized histologically and often largely suspected radio-
logically because of the presence of adipose tissue. When
the triphasic pattern is well represented, ancillary techniques
are not necessary, but in case of diagnostic doubt, the
immunohistochemical pattern is characteristic, with the
epithelioid or spindle cells expressing muscular marker
(alpha-actin and less frequently desmin) and some mel-
anocytic markers as HMB45 andMelan-A [44]. PEComas are
benign, and a simple surveillance can be recommended
if the lesion is asymptomatic and small. Large tumors
have to be removed because of the rare but real hemorrhagic
risk.
Epithelioid angiomyolipoma of the kidney is a rare dis-
ease, closely related to classic, triphasic angiomyolipoma
and considered as a potentially malignant neoplasm [45].
The epithelioid component is composed of large globulous
or plump spindle cells with clear or eosinophilic cytoplasm
and voluminous nuclei, similar to those of soft tissue
PEComas (Fig. 9). Epithelioid angiomyolipoma can be
confused with clear cell RCC or with melanoma, but
negativity of cytokeratin and PS100 and positivity of
smooth muscle markers (actin and desmin) and HMB45
and/or Melan-A are diagnostic. The minimal amount of
epithelioid component required to define angiomyolipoma as
epithelioid, and so to suspect the lesion as potentially malig-
nant, however, is not well defined. In our practice, epithelioid
features in angiomyolipomas, when present, are systematical-
ly mentioned in the pathology report with a note suggesting
that surgical removal would be performed.
The nondiagnostic biopsy
Normal renal tissue and fibrous or fibroinflammatory tissue
The proportion of biopsies composed of normal renal tissue
or sampling only fibrous or fibroinflammatory tissue varies
between 5 and 10 % in published series. Importantly, a
diagnosis of malignancy is eventually rendered in more than
half of the patients who undergo nephrectomy or repeat
biopsies, advocating the need for a second biopsy in case
of a nonconclusive biopsy [21]. A final diagnosis of scar or
pyelonephritis should strictly correlate with clinical and
radiological settings.
Necrotic tissue
Although biopsies are performed under imaging guidance in
order to be directed to viable areas, in rare cases, biopsies
a
c d
bFig. 9 Epithelioid
angiomyolipoma. Proliferation
of plump and spindle clear cells
arranged in fascicle (a,
hematoxylin and eosin ×20 and
b, hematoxylin and eosin ×40).
Immunohistochemical profile
includes intense expression of
actin (c, immunoperoxidase
×20) and partial expression of
Melan-A (d, immunoperoxi-
dase ×20)
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may exclusively sample necrotic tissue, raising the differen-
tial diagnosis of the underlying process as neoplastic versus
inflammatory. Immunohistochemistry can be helpful, as the
immunoreactivity of carcinomatous cells for CK or EMA is
usually conserved, even when necrotic.
Concluding remarks
A good morphological analysis in conjunction with the
appropriate use of an immunohistochemical panel can lead
to a precise diagnosis for a vast majority of the renal masses
sampled by core biopsy. This is now of importance because
of the need of pretherapeutic diagnosis in an increasing
number of situations. Nevertheless, definitive tumor typing
is not always possible, for example in the case of cytolog-
ically low-grade neoplasms with clear cell features or in the
case of eosinophilic cell proliferations. In those situations, it
is important to state whether the renal cell origin of the
lesion can be confirmed and to mention the nuclear grade.
Deferring the definitive diagnosis to the examination of the
surgical material appears as a reasonable option without
impending appropriate management of the patient.
Cytogenetic studies, like FISH or comparative genomic
hybridization (CGH) array, can determine changes known to
be specifically or preferentially associated with each tumor
type. For example, deletion of 3p is characteristic of
CCRCC, hyperploidy is characteristic for papillary RCC,
and hypoploidy for chromophobe RCC. This kind of ancil-
lary techniques is currently not routinely performed, with
the exception of TFE3 break-apart FISH assays for the
identification of translocation RCC. Nevertheless, FISH
and CGH array have been proven to be feasible on biopsy
samples and could be considered as an option in the future
to improve the accuracy of biopsy diagnosis [46, 47].
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